220 related articles for article (PubMed ID: 26043272)
21. α-synuclein induced synapse damage is enhanced by amyloid-β1-42.
Bate C; Gentleman S; Williams A
Mol Neurodegener; 2010 Dec; 5():55. PubMed ID: 21138585
[TBL] [Abstract][Full Text] [Related]
22. The association between prion proteins and Aβ₁₋₄₂ oligomers in cytotoxicity and apoptosis.
Hyeon JW; Kim SY; Park JS; Choi BY; Lee SM; Ju YR; An SS; Kim CK
Biochem Biophys Res Commun; 2012 Jul; 424(2):214-20. PubMed ID: 22743555
[TBL] [Abstract][Full Text] [Related]
23. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.
Falker C; Hartmann A; Guett I; Dohler F; Altmeppen H; Betzel C; Schubert R; Thurm D; Wegwitz F; Joshi P; Verderio C; Krasemann S; Glatzel M
J Neurochem; 2016 Apr; 137(1):88-100. PubMed ID: 26710111
[TBL] [Abstract][Full Text] [Related]
24. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
Hashimoto M; Rockenstein E; Crews L; Masliah E
Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
[TBL] [Abstract][Full Text] [Related]
25. The role of cytosolic phospholipase A2 α in amyloid precursor protein induction by amyloid beta1-42 : implication for neurodegeneration.
Sagy-Bross C; Kasianov K; Solomonov Y; Braiman A; Friedman A; Hadad N; Levy R
J Neurochem; 2015 Mar; 132(5):559-71. PubMed ID: 25533654
[TBL] [Abstract][Full Text] [Related]
26. Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide.
Kriem B; Sponne I; Fifre A; Malaplate-Armand C; Lozac'h-Pillot K; Koziel V; Yen-Potin FT; Bihain B; Oster T; Olivier JL; Pillot T
FASEB J; 2005 Jan; 19(1):85-7. PubMed ID: 15486059
[TBL] [Abstract][Full Text] [Related]
27. Cholesterol ester hydrolase inhibitors reduce the production of synaptotoxic amyloid-β oligomers.
McHale-Owen H; Bate C
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):649-659. PubMed ID: 29247837
[TBL] [Abstract][Full Text] [Related]
28. The glycosylphosphatidylinositol anchor is a major determinant of prion binding and replication.
Bate C; Tayebi M; Williams A
Biochem J; 2010 Apr; 428(1):95-101. PubMed ID: 20196773
[TBL] [Abstract][Full Text] [Related]
29. Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses.
Cerpa W; Dinamarca MC; Inestrosa NC
Curr Alzheimer Res; 2008 Jun; 5(3):233-43. PubMed ID: 18537540
[TBL] [Abstract][Full Text] [Related]
30. Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques in the Alzheimer's disease brain.
Takahashi RH; Tobiume M; Sato Y; Sata T; Gouras GK; Takahashi H
Neuropathology; 2011 Jun; 31(3):208-14. PubMed ID: 21062360
[TBL] [Abstract][Full Text] [Related]
31. Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration.
Bate C; Tayebi M; Williams A
Mol Neurodegener; 2010 Apr; 5():13. PubMed ID: 20374666
[TBL] [Abstract][Full Text] [Related]
32. Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by Abeta(1-42).
Bate C; Williams A
Neuropharmacology; 2007 Aug; 53(2):222-31. PubMed ID: 17583757
[TBL] [Abstract][Full Text] [Related]
33. GPI-anchor signal sequence influences PrPC sorting, shedding and signalling, and impacts on different pathomechanistic aspects of prion disease in mice.
Puig B; Altmeppen HC; Linsenmeier L; Chakroun K; Wegwitz F; Piontek UK; Tatzelt J; Bate C; Magnus T; Glatzel M
PLoS Pathog; 2019 Jan; 15(1):e1007520. PubMed ID: 30608982
[TBL] [Abstract][Full Text] [Related]
34. Effects of Acetylcholine on β-Amyloid-Induced cPLA2 Activation in the TB Neuroectodermal Cell Line: Implications for the Pathogenesis of Alzheimer's Disease.
Polverino A; Grimaldi M; Sorrentino P; Jacini F; D'Ursi AM; Sorrentino G
Cell Mol Neurobiol; 2018 May; 38(4):817-826. PubMed ID: 28993924
[TBL] [Abstract][Full Text] [Related]
35. Sialic Acid within the Glycosylphosphatidylinositol Anchor Targets the Cellular Prion Protein to Synapses.
Bate C; Nolan W; McHale-Owen H; Williams A
J Biol Chem; 2016 Aug; 291(33):17093-101. PubMed ID: 27325697
[TBL] [Abstract][Full Text] [Related]
36. Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy.
Nieznanska H; Bandyszewska M; Surewicz K; Zajkowski T; Surewicz WK; Nieznanski K
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2143-2153. PubMed ID: 29604335
[TBL] [Abstract][Full Text] [Related]
37. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
Tomiyama T
Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
[TBL] [Abstract][Full Text] [Related]
38. Current Research Therapeutic Strategies for Alzheimer's Disease Treatment.
Folch J; Petrov D; Ettcheto M; Abad S; Sánchez-López E; García ML; Olloquequi J; Beas-Zarate C; Auladell C; Camins A
Neural Plast; 2016; 2016():8501693. PubMed ID: 26881137
[TBL] [Abstract][Full Text] [Related]
39. Binding between Prion Protein and Aβ Oligomers Contributes to the Pathogenesis of Alzheimer's Disease.
Kong C; Xie H; Gao Z; Shao M; Li H; Shi R; Cai L; Gao S; Sun T; Li C
Virol Sin; 2019 Oct; 34(5):475-488. PubMed ID: 31093882
[TBL] [Abstract][Full Text] [Related]
40. Local and Use-Dependent Effects of β-Amyloid Oligomers on NMDA Receptor Function Revealed by Optical Quantal Analysis.
Sinnen BL; Bowen AB; Gibson ES; Kennedy MJ
J Neurosci; 2016 Nov; 36(45):11532-11543. PubMed ID: 27911757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
